神经科指南

订阅

MedSci主页 / 所有栏目 / 神经科指南

痴呆诊断中 PET 临床合理化应用中国专家共识 (2021版)

2021-11-25 中国微循环学会神经变性病专业委员会 中国现代神经疾病杂志

痴呆神经变性疾病

目前，全世界约有痴呆患者5000万例，截至2050年预计达1.52亿;医疗卫生投入每年约8180亿美元，占全球生产总值的1.1%。

中文标题：

痴呆诊断中 PET 临床合理化应用中国专家共识 (2021版)

发布机构：

中国微循环学会神经变性病专业委员会

发布日期：

2021-11-25

简要介绍：

痴呆是一项严重的世界性公共卫生难题，特别是随着人口老龄化的进程，其发病率逐渐升 高。痴呆发病较为隐匿，以临床症状为特征的诊断框架在实际操作中效能较低，影像学标志物证据引入 诊断系统使痴呆诊断的准确性大幅度提高。PET 显像可以在体反映痴呆的病理学过程，是痴呆诊断的 重要影像学标志物。随着国内 PET 设备在大型医疗机构的保有量迅速增长，临床诊疗过程中逐步开展 针对痴呆患者的 PET 显像，但目前 PET 显像在痴呆中的应用证据尚待进一步完善。因此有必要在现有证据的基础上结合临床实践制定合理的临床痴呆诊断中 PET 应用中国专家共识，规范其在痴呆诊断中 的应用。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=_痴呆诊断中PET临床合理化应用中国专家共识（2021版）.pdf)] GetToolGuiderByIdResponse(projectId=1, id=38af01c0022e561f, title=痴呆诊断中 PET 临床合理化应用中国专家共识 (2021版), enTitle=, guiderFrom=中国现代神经疾病杂志, authorId=0, author=, summary=目前，全世界约有痴呆患者5000万例，截至2050年预计达1.52亿;医疗卫生投入每年约8180亿美元，占全球生产总值的1.1%。, cover=https://img.medsci.cn/20211129/1638157136448_5579292.png, journalId=0, articlesId=null, associationId=2161, associationName=中国微循环学会神经变性病专业委员会, associationIntro=中国微循环学会神经变性病专业委员会, copyright=0, guiderPublishedTime=Thu Nov 25 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="page" title="Page 1"> <div class="section"> <div class="layoutArea"> <div class="column"> <p>痴呆是一项严重的世界性公共卫生难题，特别是随着人口老龄化的进程，其发病率逐渐升 高。痴呆发病较为隐匿，以临床症状为特征的诊断框架在实际操作中效能较低，影像学标志物证据引入 诊断系统使痴呆诊断的准确性大幅度提高。PET 显像可以在体反映痴呆的病理学过程，是痴呆诊断的 重要影像学标志物。随着国内 PET 设备在大型医疗机构的保有量迅速增长，临床诊疗过程中逐步开展 针对痴呆患者的 PET 显像，但目前 PET 显像在痴呆中的应用证据尚待进一步完善。因此有必要在现有证据的基础上结合临床实践制定合理的临床痴呆诊断中 PET 应用中国专家共识，规范其在痴呆诊断中 的应用。</p> <p>&nbsp;</p> </div> </div> </div> </div>, tagList=[TagDto(tagId=1195, tagName=痴呆), TagDto(tagId=5308, tagName=神经变性疾病)], categoryList=[CategoryDto(categoryId=17, categoryName=神经科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=1195, guiderKeyword=痴呆, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3167, appHits=85, showAppHits=0, pcHits=1318, showPcHits=3082, likes=1, shares=4, comments=10, approvalStatus=1, publishedTime=Mon Nov 29 12:10:04 CST 2021, publishedTimeString=2021-11-25, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=4, createdBy=null, createdName=FUNNYMAN, createdTime=Mon Nov 29 11:39:03 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 21:36:53 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=_痴呆诊断中PET临床合理化应用中国专家共识（2021版）.pdf)])
_痴呆诊断中PET临床合理化应用中国专家共识（2021版）.pdf
下载请点击：
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2093297, encodeId=ee9d209329e45, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10735431394, createdName=ms7000000598878159, createdTime=Wed Oct 12 03:12:23 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238450, encodeId=d5d912384501e, content=奥利给, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31d75319297, createdName=148a533am29暂无昵称, createdTime=Sat Aug 13 11:49:34 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212889, encodeId=6d3412128896c, content=学习，***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4955285599, createdName=148511a7m50暂无昵称, createdTime=Wed Apr 20 16:21:31 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076971, encodeId=7a0a10e697153, content=奥利给, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb45553384, createdName=小松松, createdTime=Sun Dec 05 00:35:54 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076274, encodeId=a5cd10e627440, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e555489374, createdName=且歌且行, createdTime=Thu Dec 02 17:53:09 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2022-10-12 ms7000000598878159

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2093297, encodeId=ee9d209329e45, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10735431394, createdName=ms7000000598878159, createdTime=Wed Oct 12 03:12:23 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238450, encodeId=d5d912384501e, content=奥利给, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31d75319297, createdName=148a533am29暂无昵称, createdTime=Sat Aug 13 11:49:34 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212889, encodeId=6d3412128896c, content=学习，***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4955285599, createdName=148511a7m50暂无昵称, createdTime=Wed Apr 20 16:21:31 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076971, encodeId=7a0a10e697153, content=奥利给, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb45553384, createdName=小松松, createdTime=Sun Dec 05 00:35:54 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076274, encodeId=a5cd10e627440, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e555489374, createdName=且歌且行, createdTime=Thu Dec 02 17:53:09 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2022-08-13 148a533am29暂无昵称

    奥利给

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2093297, encodeId=ee9d209329e45, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10735431394, createdName=ms7000000598878159, createdTime=Wed Oct 12 03:12:23 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238450, encodeId=d5d912384501e, content=奥利给, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31d75319297, createdName=148a533am29暂无昵称, createdTime=Sat Aug 13 11:49:34 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212889, encodeId=6d3412128896c, content=学习，***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4955285599, createdName=148511a7m50暂无昵称, createdTime=Wed Apr 20 16:21:31 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076971, encodeId=7a0a10e697153, content=奥利给, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb45553384, createdName=小松松, createdTime=Sun Dec 05 00:35:54 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076274, encodeId=a5cd10e627440, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e555489374, createdName=且歌且行, createdTime=Thu Dec 02 17:53:09 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2022-04-20 148511a7m50暂无昵称

    学习，***

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2093297, encodeId=ee9d209329e45, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10735431394, createdName=ms7000000598878159, createdTime=Wed Oct 12 03:12:23 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238450, encodeId=d5d912384501e, content=奥利给, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31d75319297, createdName=148a533am29暂无昵称, createdTime=Sat Aug 13 11:49:34 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212889, encodeId=6d3412128896c, content=学习，***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4955285599, createdName=148511a7m50暂无昵称, createdTime=Wed Apr 20 16:21:31 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076971, encodeId=7a0a10e697153, content=奥利给, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb45553384, createdName=小松松, createdTime=Sun Dec 05 00:35:54 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076274, encodeId=a5cd10e627440, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e555489374, createdName=且歌且行, createdTime=Thu Dec 02 17:53:09 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-05 小松松

    奥利给

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2093297, encodeId=ee9d209329e45, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10735431394, createdName=ms7000000598878159, createdTime=Wed Oct 12 03:12:23 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1238450, encodeId=d5d912384501e, content=奥利给, beContent=null, objectType=guider, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=31d75319297, createdName=148a533am29暂无昵称, createdTime=Sat Aug 13 11:49:34 CST 2022, time=2022-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1212889, encodeId=6d3412128896c, content=学习，***, beContent=null, objectType=guider, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c4955285599, createdName=148511a7m50暂无昵称, createdTime=Wed Apr 20 16:21:31 CST 2022, time=2022-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076971, encodeId=7a0a10e697153, content=奥利给, beContent=null, objectType=guider, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb45553384, createdName=小松松, createdTime=Sun Dec 05 00:35:54 CST 2021, time=2021-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1076274, encodeId=a5cd10e627440, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5e555489374, createdName=且歌且行, createdTime=Thu Dec 02 17:53:09 CST 2021, time=2021-12-02, status=1, ipAttribution=)]
    2021-12-02 且歌且行

    学习

    0

相关指南

提高阿尔茨海默病和相关痴呆的动物实验设计和可重复性指南：对基金提供者和研究者

阿尔茨海默病协会(AA,Alzheimer&#039;s Association) · 2016-10-25

中药新药用于痴呆的临床研究技术指导原则（征求意见稿）

国家药品监督管理局药品审评中心（CDE） · 2019-10-31

2019 WHO指南：降低认知能力下降和痴呆的风险

世界卫生组织(WHO,The World Health Organization) · 2019-05-10

同型半胱氨酸与痴呆：国际共识声明

国外神经内科相关专家小组（统称） · 2019-02-20

2019 AAGBI指南：痴呆患者围术期管理

大不列颠爱尔兰麻醉学会(AAGBI,Association of Anaesthetists of Great Britain and Ireland) · 2019-02-10

重视痴呆的诊断和生活质量提高 ——2018 NICE《痴呆的评估和管理指南》解读

暂未更新 · 2018-11-20

拓展阅读

EFNS指南：离子通道病、癫痫、偏头痛、卒中和痴呆的分子诊断

欧洲神经科学协会联盟(EFNS,European Federation of Neurological Societies) · 2010-01-01

2010中华医学会 中国痴呆与认知障碍诊治指南：轻度认知障碍的诊断和治疗

中华医学会神经病学分会 · 2010-11-01

2011中华医学会 中国痴呆与认知障碍诊治指南（四）:辅助检查及其选择

中华医学会神经病学分会 · 2011-01-01

2011中华医学会 中国痴呆与认知障碍诊治指南（五）:痴呆治疗

中华医学会神经病学分会 · 2011-01-01

中国痴呆与认知障碍诊治指南(二)：痴呆分型及诊断标准

中华医学会神经病学分会痴呆与认知障碍学组 · 2011-03-08

中国痴呆与认知障碍诊治指南（一）：痴呆诊断流程

中华医学会神经病学分会痴呆与认知障碍学组 · 2011-03-08